Mesoblast (ASX:MSB) disclosed FY2026 net revenue of US$115 million and gross profit on total sales of US$110 million, excluding amortisation expense, during its ASX Investor Day presentation in November 2026, covering the first full year of its U.S. commercial launch of RYONCIL.

Key Points

  • FY2026 net revenue of US$115 million and gross profit on total sales, excluding amortisation expense, of US$110 million reported for the first full year post RYONCIL launch
  • 350 patients completed in the Phase 3 trial for the chronic low back pain indication
  • Mesoblast entered into a US$125.0 million five-year non-dilutive credit-line facility, consolidating and retiring two higher cost facilities
  • FDA cleared the Investigational New Drug application for the Pediatric Duchenne's Phase 3 trial
  • Registration trial for RYONCIL label extension into adults with steroid-refractory acute graft versus host disease commenced and is currently enrolling patients, targeting 40 sites across the U.S.

FY2026 Financial Results and RYONCIL Commercial Launch

According to the filing, Mesoblast recorded FY2026 net revenue of US$115 million from the U.S. commercial launch of RYONCIL, described as the first and only mesenchymal stromal cell product approved by the U.S. Food and Drug Administration. Gross profit on total sales, excluding amortisation expense, was US$110 million. The company's commercial infrastructure includes more than 50 transplant centres onboarded, 98% of U.S. lives covered, and a J-code obtained to support market access across transplant centres and specialists.

Clinical Pipeline Milestones Across Multiple Indications

The filing disclosed that Mesoblast completed enrolment of 350 patients in the Phase 3 trial for the chronic low back pain indication and received FDA alignment on filing for approval in the end-stage heart failure indication. The registration trial for a RYONCIL label extension into adults with steroid-refractory acute graft versus host disease commenced and is currently enrolling patients across a targeted 40 U.S. sites, with the trial designed to enrol 180 Grade III/IV steroid-refractory acute graft versus host disease adults. The FDA also cleared the Investigational New Drug application for the Pediatric Duchenne's Phase 3 trial.

US$125 Million Non-Dilutive Credit Facility and Intellectual Property Position

Mesoblast disclosed it entered into a US$125.0 million five-year non-dilutive credit-line facility during FY2026, with the proceeds used to consolidate and retire two higher cost facilities. The company's filing also noted a global intellectual property portfolio comprising more than 1,100 patents and patent applications providing protection through beyond 2044. Regional licensing arrangements are in place with JCR Pharmaceuticals for Japan, Grünenthal for chronic low back pain in Europe and Latin America/Caribbean, and Tasly Pharmaceuticals for chronic heart failure in China.